GlassScriptPhysician profile
Gabriel Guerrero
NPI 1285738831
$66,294.83
in general payments reported to CMS, 2019-2025
22 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $8,414 · 2021: $9,150 · 2022: $5,604 · 2023: $358 · 2024: $501 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.28 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $27,275.71 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $26,518.27 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $7,491.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $3,815.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $534.59 | 2021-2025 | |
| Lilly USA, LLC | $123.58 | 2023-2025 | Jardiance, Mounjaro |
| Medtronic, INC. | $98.15 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbott Laboratories | $85.80 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $53.62 | 2020 | |
| Tandem Diabetes Care, INC. | $39.13 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Roche Diabetes Care, INC. | $35.50 | 2020 | |
| Beta Bionics, INC. | $29.85 | 2024 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $29.74 | 2019 | |
| Insulet Corporation | $23.66 | 2024 | Omnipod |
| Corcept Therapeutics | $22.04 | 2023 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $21.98 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $19.43 | 2025 | Exparel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Shire North American Group INC | $18.45 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.86 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.08 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $6.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.